Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 12, 2014, Pages 8312-8321

  Deng, Qiuhua ^a   Yang, Haihong ^a,b   Lin, Yongping ^a   Qiu, Yuan ^a,b   Gu, Xia ^a   He, Ping ^a   Zhao, Meiling ^a,b   Wang, Hui ^a   Xu, Yunjian ^a   Lin, Yunen ^a   Jiang, Juhong ^a   He, Jianxing ^a,b   Zhou, Jeff X ^c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Respiratory Disease   (China)

^c NINGBO UNIVERSITY   (China)

Author keywords

Breast cancer; ERCC1; Expression; Gastric cancer; mRNA; NSCLC; Prognostic factor

Indexed keywords

DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; CHINA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84921501114     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Kosmidis E. Chemotherapy in NSCLC: historical review. Lung Cancer 2002; 38: 19-22.
2. WHO. Cancer incidence in five continents V01. IX. Lyon: International Agency for Research on Cancer; 2007.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008; GlOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
4. Pfannschmidt J, Muley I, Bulzebruck H, Hof-fmann H, Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007; 55: 371-377.
5. Sun Y, Shi YK, Wang JW, et al. Clinical Medical Oncology Handbook, 5.0 edition. Beijing: Peo-ple's Medical Publishing House; 2009. pp. 476-491.
6. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lun Cancer, A Meta-Analysis of the Published Literature. J Clin Oncol 2005; 23: 2926-2936.
7. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Impacts of excision repair cross complementing gene 1(ERCC1). dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008; 98: 832-839.
8. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer Chemotherapy. Cancer Treat Rev 1998; 24: 331-344.
9. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20: 435-439.
10. Ahaha R, Lisng X, Yu JJ, Reed E. Excision repair cross complementing group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14: 959-970.
11. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Ca-mps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung caner. J Clin Oncol 2007; 25: 2747-54.
12. Ozkan C, Gumuskaya B, Yaman S, Aksoy S, Guler G, Altundag K. ERCC1 expression in triple negative breast cancer. J BUON 2012; 17: 271-6.
13. Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008; 4: 6401-7.
14. Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res 2012; 31: 25.
15. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pi-rker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.
16. Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele BN, Erasmus JJ, Hofstetter WL, Komaki R, Mehran RJ, Moran CA, Pisters KM, Rice DC, Walsh GL, Roth JA. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg 2009; 138: 412-18.
17. Chae S, Lee A, Lee JH. The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification. Gastric Cancer 2011; 14: 166-171.
18. Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Kim S, Choe JH, Lee JE, Kim JH, Kim JS, Nam SJ, Yang JH. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 2011; 126: 471-478.
19. Lu HY, Su D, Pan XD, Jiang H, Ma SL. Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer. Oncol Lett 2012; 3: 415-420.
20. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival resected patients with non-small cell lung cancer. Chest 2005; 127: 978-83.
21. Olaussen KA, Fouret P, Kroemer G. ERCC1-specific immunostaining in non-small-cell lung cancer. New Engl J Med 2007; 357: 1559-61.
22. Wang YN, Lv JC, Zeng BH. Expression of DNA repair gene ERCC1 and its relationship with PAH-DNA adducts in lung cancer tissues. Chinese Journal of Pathophysiology 2004; 20: 1153-1156.
23. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danen-berg KD, Danenberg PV, Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91.
24. Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008; 8: 386.
25. Li Q, Dang CX, Liu ZG. ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy. The Chinese-German Journal of Clinical Oncology 2011; 10: 92-95.
26. Xu DZ, Mao GX. Expression and prognostic significance of ERCC1 protein in gastric cancer. Medical Journal of Communications 2010; 4: 375-377.
27. Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, Albergaria A, Schmitt F. Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract 2013; 209: 331-336.